Methylselenol, a selenium metabolite, plays common and different roles in cancerous colon HCT116 cell and noncancerous NCM460 colon cell proliferation

Nutrition and Cancer

Volumn 64, Issue 1, 2012, Pages 128-135

  Zeng, Huawei ^a   Briske Anderson, Mary ^a   Wu, Min ^b   Moyer, Mary P ^c  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b UNIVERSITY OF NORTH DAKOTA   (United States)

^c INCELL Corporation ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME; FOCAL ADHESION KINASE; METHIONASE; METHYLSELENOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN TYROSINE KINASE; SELENIUM DERIVATIVE; SELENOMETHIONINE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HCT116; CELL SURVIVAL; COLON CELL; CONCENTRATION (PARAMETERS); DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INTESTINE CELL; INTRACELLULAR SIGNALING; ONCOGENE C MYC; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE; CELL PROLIFERATION; COLON; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FOCAL ADHESION KINASE 1; G1 PHASE; HUMANS; METHANOL; MITOGEN-ACTIVATED PROTEIN KINASES; ORGANOSELENIUM COMPOUNDS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-MYC; S PHASE; SIGNAL TRANSDUCTION;

EID: 84856822850     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.630555     Document Type: Article

References (40)

1. Goulet AC, Watts G, Lord JL, and Nelson MA: Profiling of selenomethionine responsive genes in colon cancer by microarray analysis. Cancer Biol Ther 6, 494-503, 2007. (Pubitemid 47328322)
2. Whanger PD: Selenium and its relationship to cancer: An update. Br J Nutr 91,11-28, 2004. (Pubitemid 38100556)
3. Meyer F, Galan P, Douville P, Bairati I, Kegle P,.et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 116, 182-186, 2005. (Pubitemid 40967253)
4. Amaral AF, Cantor KP, Silverman DT, and Malats N. Selenium and bladder cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev 19, 2407-2415, 2010.
5. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 128, 1845-1854, 1998. (Pubitemid 28509845)
6. Combs GF Jr.: Current evidence and research needs to support a health claim for selenium and cancer prevention. J Nutr 135, 343-347, 2005. (Pubitemid 40194505)
7. Clark LC, Combs GF Jr., Turnbull BW, Clark LC, Combs GF Jr.,.et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin.Arandomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276, 1957-1963, 1996. (Pubitemid 26427723)
8. Combs GF Jr. and Gray WP: Chemopreventive agents: selenium. Pharmacol Ther 79, 179-192, 1998. (Pubitemid 28393874)
9. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM,.et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301, 39-51, 2009.
10. Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH,.et al. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res 3, 1035-1043, 2010.
11. Rayman MP, Combs GF Jr., and Waters DJ: Selenium and vitamin E supplementation for cancer prevention. JAMA 301, 1876, 2009.
12. Cai XJ, Block E, Uden PC, Xhang X, Quimby BD, and Sullivan JJ: Allium chemistry: Identification of selenoamino acids in ordinary and seleniumenriched garlic, onion and broccoli using gas chromatography with atomic emission detection. J Agric Food Chem 43, 1754-1757, 1995.
13. Davis CD, Zeng H, and Finley JW: Selenium-enriched broccoli decreases intestinal tumorigenesis in multiple intestinal neoplasia mice. J Nutr 132, 307-309, 2002. (Pubitemid 34135613)
14. Ganther HE: Seleniummetabolism, selenoproteins and mechanisms of cancer prevention: Complexities with thioredoxin reductase. Carcinogenesis 20, 1657-1666. 1999. (Pubitemid 29410542)
15. Lu J and Jiang C. Antiangiogenic activity of selenium in cancer chemoprevention: Metabolite-specific effects. Nutr Cancer 40, 64-73, 2001. (Pubitemid 34037516)
16. Rayman MP: Selenium in cancer prevention: A review of the evidence and mechanism of action. Proc Nutr Soc 64, 527-542. 2005. (Pubitemid 41705454)
17. Zeng H, Wu M, and Botnen JH: Methylselenol, a selenium metabolite, induces cell cycle arrest in g1 phase and apoptosis via the extracellularregulated kinase 1/2 pathway and other cancer signaling genes. J Nutr 139, 1613-1618. 2009.
18. JacksonMI and CombsGF Jr.: Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care 11, 718-726, 2008.
19. Miki K, Xu M, Gupta A, Ba Y, Tan Y,.et al. Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res 61, 6805-6810, 2001. (Pubitemid 32896504)
20. Moyer MP, Manzano LA, Merriman RL, Stauffer JS, and Tanzer LR: NCM460, a normal human colon mucosal epithelial cell line. In Vitro Cell Dev Biol Anim 32, 315-317, 1996.
21. Zeng H, Briske-Anderson M, Idso JP, and Hunt CD: The selenium metabolite methylselenol inhibits the migration and invasion potential of HT1080 tumor cells. J Nutr 136, 1528-1532, 2006. (Pubitemid 43765357)
22. Pinto JT, Lee JI, Sinha R, Macewan ME, and Cooper AJ: Chemopreventive mechanisms of alpha-keto acid metabolites of naturally occurring organoselenium compounds. Amino Acids. 41, 29-41, 2011.
23. Sato D and Nozaki T.Methionine gamma-lyase: The unique reaction mechanism, physiological roles, and therapeutic applications against infectious diseases and cancers. IUBMB Life 61, 1019-1028, 2009.
24. Brattain MG, Fine WD, Khaled FM, Thompson J, and Brattain DE: Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41, 1751-1756, 1981. (Pubitemid 11114567)
25. Chang L and Karin M. Mammalian MAP kinase signaling cascades. Nature 410, 37-40, 2001. (Pubitemid 32225829)
26. Mercer BA andD'Armiento JM: Emerging role ofMAP kinase pathways as therapeutic targets in COPD. Int J Chron Obstruct Pulmon Dis 1, 137-150, 2006.
27. Zeng H. Selenium as an essential micronutrient: Roles in cell cycle and apoptosis. Molecules 14, 1263-1278, 2009.
28. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A,.et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5, 810-816, 1999. (Pubitemid 29318616)
29. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC,.et al. The c-Myc target gene network. Semin Cancer Biol 16, 253-264, 2006. (Pubitemid 44311039)
30. Dang CV: C-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19, 1-11, 1999. (Pubitemid 29018404)
31. Adhikary S and Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6, 635-645, 2005. (Pubitemid 41081267)
32. Erisman MD, Rothberg PG, Diehl RE, Morse CC, Spandorfer JM,.et al. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Mol Cell Biol 5, 1969-1976, 1985. (Pubitemid 15049156)
33. Frisch SM and Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol 13, 555-562, 2001. (Pubitemid 32817013)
34. Reddig PJ and Juliano RL: Clinging to life: Cell to matrix adhesion and cell survival. Cancer Metastasis Rev 24, 425-439, 2005. (Pubitemid 41569982)
35. Demers MJ, Thibodeau S, Nöel D, Fujita N, Tsuruo T,.et al. Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling toMEK/Erk and/or PI3-K/Akt-1. J Cell Biochem 107, 639-654, 2009.
36. Zhao J and Guan JL: Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 28, 35-49. 2009.
37. Frisch SM, Vuori K, Ruoslahti E, and Chan-Hui PY: Control of adhesiondependent cell survival by focal adhesion kinase. J Cell Biol 134, 793-799, 1996. (Pubitemid 26269148)
38. Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks SK,.et al. Anti-apoptotic role of focal adhesion kinase (FAK): Induction of inhibitorof- apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem275, 16309-16315, 2000. (Pubitemid 30366946)
39. Gatenby RA and Vincent TL: An evolutionary model of carcinogenesis. Cancer Res 63, 6212-6220, 2003. (Pubitemid 37255166)
40. Rajamanickam S and AgarwalR:Natural products and colon cancer: Current status and future prospects. Drug Dev Res 69, 460-471, 2008.